 |
| Andres Poveda |
Maintenance Olaparib Improves OS in Patients With BRCA-Mutated, Relapsed Ovarian Cancer
The SOLO2 clinical trial has now concluded, there is data available for the 5 years follow up of patients who received Olaparib therapy. Patients were selected as being BRCA mutation positive and having had at least 2 previous platinum chemo courses.
The primary end point, an improvement in progression free survival was reported in 2017 and has caused a significant change in the treatment of ovarian cancer, with Olaparib maintenance now being standard therapy for some patients.
The secondary end point is improvement in overall survival; it is a feature of many oncology clinical trials that this is not achieved. However, analysis of the final data as of February 2020 shows significant improvement in overall survival with a median of 51.7 months compared to 38.8 months for the placebo group.
This trial confirms the value of Olaparib therapy, which is now suitable for increasing numbers of ovarian cancer patients who fit in the homologous recombination deficiency group.
No comments:
Post a Comment